Managers / Q4 2025 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $117M in U.S.-listed holdings across 20 positions for Q4 2025.
The portfolio is heavily concentrated: PAGPEUR alone accounts for 20.8% of reported value.
Compared with Q3 2025, the fund opened 8 new positions and exited 4.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.0% · $103M
- ADR · 9.0% · $11M
- Other · 2.9% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KYTXKYVERNA THERAPEUTICS INC | NEW | +666.7K | 666.7K | +$6M | $6M |
| IVAINVENTIVA SA - ADR | NEW | +1.00M | 1.00M | +$5M | $5M |
| OCULIS HOLDING AG | NEW | +172.8K | 172.8K | +$3M | $3M |
| SABSSAB BIOTHERAPEUTICS INC | NEW | +652.9K | 652.9K | +$2M | $2M |
| RGNXREGENXBIO INC | NEW | +116.9K | 116.9K | +$2M | $2M |
| LENZLENZ THERAPEUTICS INC | NEW | +59.1K | 59.1K | +$945,360 | $945,360 |
| AARDAARDVARK THERAPEUTICS INC | NEW | +46.4K | 46.4K | +$609,105 | $609,105 |
| KLRSKALARIS THERAPEUTICS INC | NEW | +42.1K | 42.1K | +$354,927 | $354,927 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.